Vanda Imsidolimab PDUFA Dec 12: GPP Market Goes Two-Player

The FDA accepted Vanda Pharmaceuticals’ (VNDA) Biologics License Application for imsidolimab in generalized pustular psoriasis (GPP) with a PDUFA target action date of December 12, 2026. The stock closed at $5.18 on July 24, giving the company a market cap near $312 million.

GPP is a rare, life-threatening autoinflammatory skin disorder characterized by sudden flares of widespread pustules, erythema, and systemic symptoms including fever. Many cases trace to genetic variants in the IL36RN gene, which encodes the IL-36 receptor antagonist. Excessive IL-36 signaling drives the disease. Imsidolimab is a fully humanized IgG4 monoclonal antibody that blocks the IL-36 receptor, directly targeting that pathway.

What the Data Showed

The BLA rests on two registrational studies, GEMINI-1 and GEMINI-2. In the efficacy analysis, a single intravenous dose of imsidolimab produced clear or almost clear skin (GPPPGA 0/1) in 53% of patients at Week 4, compared to 13% on placebo. That is the primary endpoint and it cleared the bar comfortably.

The maintenance data is where imsidolimab separates itself. Over approximately two years of monthly dosing, no flares occurred in the active treatment arm. Zero. For a disease defined by recurrent, unpredictable flares that can hospitalize patients, that is the number that matters most for commercial positioning. The drug also showed a low incidence of anti-drug antibodies, an advantage over less fully humanized competitors.

The Competitive Picture

If approved, imsidolimab enters a two-drug market. Boehringer Ingelheim’s Spevigo (spesolimab), another anti-IL-36 receptor antibody, received FDA approval in September 2022 for GPP flares. Spevigo validated the IL-36 target and proved the mechanism works. Imsidolimab would be the second entrant.

Vanda did not discover the molecule. The company holds an exclusive global license from AnaptysBio (ANAB), which originally developed the drug through the GEMINI program before out-licensing to Vanda. The deal structure involves milestones and royalties to AnaptysBio, meaning Vanda captures the commercial upside but not the full economics.

Vanda has had a busy 12 months. The FDA approved NEREUS (tradipitant) for motion sickness and BYSANTI (milsaperidone), making imsidolimab the third potential approval in a year. For a $312 million company, three drug approvals in 12 months is unusual throughput, though the revenue contribution from the first two remains modest.

What to Watch

The December 12 PDUFA is 140 days out. The main risk is regulatory, not clinical: the GEMINI data is clean and the IL-36 mechanism is already validated by Spevigo’s approval. The commercial question is whether a second-to-market antibody can wrest share from an entrenched incumbent in a disease with roughly 2 to 124 cases per million worldwide. For a framework on how FDA decision deadlines work, see our guide to PDUFA dates.

Source: Vanda Pharmaceuticals BLA acceptance press release